Healthcare and Life Science
H.E.L Group strengthens leadership team to focus on new product development and enhanced customer support
Alan Lockley joins as Director of Global Services, Edward Quinn as Director of Product Development and Mark Appleton takes new role as Director of Research. ...
PhoreMost enters multi-project drug target discovery collaboration with Roche
PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes. ...
Guardtech going for gold at four awards evenings in space of four months
The cleanroom construction Group are up for five honours at glitzy showpieces in London and Cambridgeshire. ...
Avacta announces AVA6000 receives Orphan Drug Designation from the US Food and Drug Administration
London and Wetherby, UK - Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...
Global Access Diagnostics acquires manufacturing rights for IT-LEISH rapid diagnostic test from Bio-Rad Laboratories
Bedford, UK - Global Access Diagnostics (GADx), a social enterprise prioritising equitable access to diagnostics and driving local manufacturing, announces it has acquired the manufacturing rights for the IT-LEISH rapid diagnostic test (RDT) for visceral leishmaniasis (VL) from Bio...
Why isn’t Adaptability more of a priority?
Well, when I put that question to the talented members of the Scottish Institute for Business Leaders this week, their wide-ranging and insightful answers included a clutch of stand-out insights: • It’s a complex concept • Too much energy is required • It’s not easy to...
Oxford Innovation Space appoints Gary Jennings as new Innovation Director at The Epicentre, Haverhill
Oxford Innovation Space has appointed Gary Jennings as the new Innovation Director at The EpiCentre in Haverhill alongside Centre Manager, Andrew Bell. Gary has many years’ experience of promoting healthcare businesses. “I am very pleased to be taking on this new role having worked in...
Constructive Bio to build on synthetic biology breakthroughs
Medical Research Council’s (MRC) Laboratory of Molecular Biology launches a new spinout company, Constructive Bio, which secured $15 million seed investment. ...
Avacta announces Phase I clinical study of AVA6000 to advance to the fourth cohort
London and Wetherby, UK - Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin will advanc...